DAFTAR PUSTAKA

Alam, A., 2016. Kejadian Meningitis Bakterial pada Anak usia 6-18 bulan yang Menderita Kejang Demam Pertama. *Sari Pediatri,* 13(4), pp. 293-8.

Aljunid, S. dkk., 2011. Impact of routine PCV 7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. *BMC Infectious Diseases,* 11(1), p. 248.

Aminullah, A., Hadisaputro, S., Soemantri, A. & Suhartono, S., 2016. Kadar Oksidan yang Tinggi Sebagai Faktor Risiko Terjadinya Hemolisis pada Neonatus Sepsis. *Sari Pediatri,* 14(3), pp. 198-204.

Andayani, T. M., 2013. *Farmakoekonomi prinsip dan metodologi.* Yogyakarta: Bursa Ilmu.

Anh, D. D. dkk., 2010. Treatment Costs of Pneumonia, Meningitis, Sepsis, and Other Diseases among Hospitalized Children in Viet Nam. *Journal of Health, Population and Nutrition,* 28(5), pp. 436-442.

Ardianti , S., Budiono, U. & Ciptaningtyas, R., 2013. Pola Kuman Pada Pasien Sepsis yang Dirawat di ICU RSUP Dr. Kariadi Semarang: Periode 1 Januari–31 Desember 2011. Semarang: *Doctoral dissertation,* Faculty of Medicine University Diponegoro.

Aspesberro, F., Mangione-Smith, R. & Zimmerman, J. J., 2015. Health-related quality of life following pediatric critical illness. *Intensive Care Medicine,* 41(7), pp. 1235-1246.

Atti, M. C. d. dkk., 2014. In-hospital management of children with bacterial meningitis in Italy. *Italian Journal of Pediatrics,* 40(1), pp. 1-7.

Black, S. dkk., 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *The Pediatric Infectious Disease Journal,* 19(3), pp. 187-195.

Black, S. dkk., 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. *The Pediatric Infectious Disease Journal,* 21(9), pp. 810-815.

Bluestone, C. D. & Klein, J. O., 2007. *Otitis media in infants and children.* USA: PMPH.

Bluestone, C. D., Stephenson, J. S. & Martin, L. M., 1992. Ten-year review of otitis media pathogens. *The Pediatric Infectious Disease Journal,* 11(8), pp. S7-11.

Bootman, J. L., Towsend, R. J. & McGhan, W. F., 2005. *Principles of Pharmacoeconomics.* 3rd ed. USA: *Harvey Whitney Books Company.*

Badan Pusat Statistik DIY, 2020. Upah Minimum Provinsi di DI Yogyakarta (rupiah) 2018-2020. yogyakarta.bps.go.id. [*Online*]. *Available* at: https://yogyakarta.bps.go.id/indicator/6/272/1/upah-minimum-kabupaten-upah-minimum-provinsi-di-di-yogyakarta.html. [Diunduh 23 Januari 2020].

Badan Pusat Statistik, 2020. *GDP Indonesia Tahun 2019,* Jakarta: Badan Pusat Statistik.

Briggs, A., Sculpher, M. & Karl, C., 2006. Decision Modeling for Health Economic Evaluation. *Oup Oxford.*

Brouwer, M. C., Tunkel, A. R. & van de Beek, D., 2010. Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. *Clinical Microbiology Reviews,* 23(3), pp. 467-492.

Centers for Disease Control and Prevention (CDC), 2006. Vaccine preventable deaths and the Global Immunization Vision and Strategy. *Morbidity and Mortality weekly report,* 55(18), p. 511.

Centers for Disease Control and Prevention (CDC), 2010. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. *Morbidity and mortality weekly report,* 59(9), pp. 258-261.

Chaudhuri, A. dkk., 2008. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. *European Journal of Neurology,* 15(7), pp. 649-659.

Che, D., Zhou, H., He, J. & Wu, B., 2014. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. *BMC health services research,* 14(1), pp. 1-14.

Chen, K. & Pohan, H. T., 2000. *Ilmu Penyakit Dalam.* 3rd ed. Jakarta: FKUI.

Chuck, A. W., Jacobs, P., Tyrrell, G. & Kellner, J. D., 2010. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. *Vaccine,* 28(33), pp. 5485-5490.

Claeson, M., Gillespie, D., Mshinda , H. & Troedsson, H., 2003. Bellagio Study Group on Child Survival: Knowledge into action for child survival. *The Lancet,* 362(9380), pp. 323-327.

Constenla, D. dkk., 2007. The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean. *Sabin Vaccine Institute, Volume* 1, p. 129.

Cutts, F. dkk., 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *The Lancet,* 365(9465), pp. 1139-1146.

Destarac, L. A. & Ely, E. W., 2001. *Sepsis in Older Patients : An Emerging Concern in Critical Care*. *Advances in sepsis,* 2(1), pp. 15-22.

Devlin, N. J. & Krabbe, P. F., 2013. *The Development of New Research Methods for The Valuation of EQ-5D-5L*. s.l.:s.n.

Dinas Kesehatan, D., 2017. *Profil Kesehatan Provinsi DI Yogyakarta Tahun 2017*. Yogyakarta: Dinas Kesehatan DIY.

Drummond, M. dkk., 2009. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. *Value in Health,* 12(4), pp. 409-418.

Drummond, M. F. dkk., 2015. *Methods for the economic evaluation of health care programmes.* Inggris: Oxford university press.

Earnshaw, S. R. dkk., 2012. Cost-effectiveness of 2+ 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. *BMC infectious diseases,* 12(1), pp. 1-13.

European Medicines Agency (EMA), 2009. *European Medicines Agency.* [Online] Available at: www.ema.europa.eu.

Esposito, S. dkk., 2002. Characteristics of Streptococcus pneumoniae and Atypical Bacterial Infections in Children 2–5 Years of Age with Community-Acquired Pneumonia. *Clinical Infectious Diseases,* 35(11), pp. 1345-1352.

Faridah, N., Machlaurin, A. & Subagio, P. B., 2016. *Analisis Efektivitas Biaya Penggunaan Antibiotik terhadap Pasien Sepsis Pediatrik di Rawat Inap RSD dr. Soebandi Kabupaten Jember pada Tahun 2014* (*Cost effectiveness Analysis of Antibiotics in Hospitelized Pediatric Sepsis Patients at RSD dr. Soebandi Je*). Pustaka Kesehatan, 4(2), pp. 255-262.

Farida, H. dkk., 2014. Nasopharyngeal Carriage of Streptococcus pneumonia in Pneumonia-Prone Age Groups in Semarang, Java Island, Indonesia. *PloS one,* 9(1), p. 87431.

Floyd, J. dkk., 2015. Evaluating the impact of pulse oximetry on childhood pneumonia mortality in resource-poor settings. *Nature,* 528(7580), pp. S53-S59.

Flynn, C. A., Griffin, G. & Tudiver, F., 2002. Decongestants and antihistamines for acute otitis media in children. *Cochrane Library,* 1.

Ginsberg, L., 2004. Difficult and recurrent meningitis. *Journal of Neurology, Neurosurgery & Psychiatry,* 75(1), pp. i16-i21.

Grijalva, C. G. dkk., 2007. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. *The Lancet,* 396(9568), pp. 1179-1186.

Haasis, M. A. dkk., 2015. o Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines. *PLoS one,* 10(7), p. e0131156.

Hadning, I., Ikawati, Z. & Andayani, T. M., 2015. Stroke Treatment Cost Analysis for Consideration on Health Cost Determination Using INA-CBGs. *International Journal of Public Health Science,* 4(4), pp. 288-293.

Hamer, D. dkk., 2015. Etiology of Bacteremia in Young Infants in Six Countries. *The Pediatric Infectious Disease Journal,* 34(1), pp. 1-8.

Hansen, J. dkk., 2006. Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of Pneumonia: Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs. *The Pediatric Infectious Disease Journal,* 25(9), pp. 779-781.

Harris, M. dkk., 2011. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. *Thorax,* 66(2), pp. 1-23.

Hartati, S., 2011. *Analisis faktor risiko yang berhubungan dengan kejadian pneumonia pada anak balita di RSUD Pasar Rebo Jakarta*. Jakarta: Magister Ilmu Keperawatan Universitas Indonesia.

Hassanah, N. M., Lestari, H. & Rasma, R., 2016. Analisis Faktor Risiko Jenis Kelamin Bayi, Bblr, Persalinan Prematur, Ketuban Pecah Dini Dan Tindakan Persalinan Dengan Kejadian Sepsis Neonatus Di Rumah Sakit Bahteramas Provinsi Sulawesi Tenggara Tahun 2016. *Jurnal Ilmiah Mahasiswa Kesehatan Masyarakat*, 1(3).

Heyderman, R. S. dkk., 2003. Early management of suspected bacterial meningitis and meningococcal septicaemia in adults. *Journal of Infection*, 46(2), pp. 75-77.

Hussain, H. dkk., 2008. Economic analysis of childhood pneumonia in Northern Pakistan. *Health Policy and Planning*, 23(6), pp. 438-442.

Hu, S. dkk., 2014. Estimating the Cost-Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Shanghai, China. *Value in Health Regional Issues*, 3, pp. 197-204.

Jauneikaite, E., Jefferies, J. M., Hibberd, M. L. & Clarke, S. C., 2012. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: A review. *Vaccine*, 30(24), pp. 3503-3514.

Kang, C.-I. & Song, J.-H., 2013. Antimicrobial resistance in Asia: current epidemiology and clinical implications. *Infection & chemotherapy*, 45(1), p. 22.

Kementerian Kesehatan, 2016. *Peraturan Menteri Kesehatan Republik Indonesia, Nomor 64 Tahun 2016, tentang Perubahan Atas Peraturan Menteri Kesehatan Nomor 52 Tahun 2016 tentang Standar Tarif Pelayanan Kesehatan dalam Penyelenggaraan Program Jaminan Kesehatan*. Jakarta: Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan, 2018. *Riset Kesehatan Dasar Badan Penelitian & Pengembangan Kesehatan*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan, 2020. *Indonesia Tegaskan Komitmen Pencegahan Pneumonia di Forum Internasional*. [*Online*] *Available* at: https://www.kemkes.go.id/article/print/20013100002/indonesia-tegaskan-komitmen-pencegahan-pneumonia-di-forum-internasional.html. [Diunduh 21 Juli 2021].

Kementerian Kesehatan, 2021. *Vaksinasi PCV Masuk Program Imunisasi Rutin, Jatim dan Jabar Jadi Lokasi Pertama Pencanangan*. [*Online*] *Available* at: https://www.kemkes.go.id/article/print/20013100002/indonesia-tegaskan-komitmen-pencegahan-pneumonia-di-forum-internasional.html. [Diunduh 21 Juli 2021].

Kim, S.-Y., Gene, L. & Sue, J. G., 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. *BMC infectious diseases*, 10(1), pp. 1-18.

Klugman, K. P. dkk., 2003. A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection. *New England Journal of Medicine*, 349(14), pp. 1341-1348.

Kozyrskyj, A. L. dkk., 1998. Treatment of Acute Otitis Media With a Shortened Course of Antibiotics: A Meta-analysis. *JAMA*, 279(21), pp. 1736-1742.

Kulpeng, W. dkk., 2013[a]. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?. *Vaccine,* 31(26), pp. 2839-2847.

Kulpeng, W. dkk., 2013[b]. Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. *BMC Pediatrics,* 13(1), p. 122.

Lagos, R. dkk., 2008. Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. *The Journal of Infectious Diseases,* 198(12), pp. 1809-1817.

Lee, K. K. C. dkk., 2013. The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong. *Value in Health Regional Issues,* 2(1), pp. 64-74.

Legood, R. dkk., 2009. Health related quality of life in survivors of pneumococcal meningitis. *Acta Paediatrica,* 98(3), pp. 543-547.

Levine, O. S. dkk., 2010. Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. *Current opinion in infectious diseases,* 23(3), pp. 236-241.

Lieu, T. A. dkk., 2000. Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children. *JAMA,* 283(11), pp. 1460-1468.

MacKinnon III, G. E., 2011. *Understanding Health Outcomes and Pharmacoeconomics.* Burlington: Jones & Bartlett Publishers.

Mokkad, A. H. dkk., 2016. Global burden of diseases, injuries, and risk factors for young people's health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet,* 387(10036), pp. 2383-2401.

Mulyadi, 2005. *Akuntansi Biaya.* 5th ed. Yogyakarta: UPP AMP YKPN.

Nathan, J. J. dkk., 2013. Prevalence of macrolide resistance and in vitro activities of six antimicrobial agents against clinical isolates of Streptococcus pneumoniae from a multi-center surveillance in Malaysia. *Med J Malaysia,* 68(2), pp. 119-124.

Nurjannah, dkk., 2011. Insidens Diare pada Anak dengan Pneumonia, Studi Retrospektif. *Sari Pediatri,* 13(3), pp. 169-173.

Oemar, M. & Janssen, B., 2013. *EQ-5D-5 L user guide-basic information on how to use the EQ-5D-5 L instrument.* Rotterdam: EuroQol Group.

Paradiso, P. R., 2011. Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children. *Clinical Infectious Diseases,* 52(10), pp. 1241-1247.

Pavia, M. dkk., 2009. Efficacy of Pneumococcal Vaccination in Children Younger Than 24 Months: A Meta-Analysis. *Pediatrics,* 123(6), pp. e1103-e1110.

Principi, N. & Esposito, S., 2016. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. *International journal of molecular sciences,* 18(1), p. 30.

Purba, F. D. dkk., 2017. The Indonesian EQ-5D-5L Value Set. *PharmacoEconomics,* 35(11), pp. 1153-1165.

Rabin, R., Oemar, M. & Oppe, M., 2013. *User guide: basic information on how to use the EQ-5D-3L instrument.* Rotterdam: Euroqol Group.

Reeder, C. E., 1995. Overview of Pharmacoeconomics and Pharmaceutical Outcomes Evaluations. *American journal of health-system pharmacy, ASHP*, 330(3), pp. 679-686.

Rozenbaum, M. H. dkk., 2010. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. *Bmj,* 340.

Rudan, I. dkk., 2013. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. *Journal of Global Health,* 3(1).

Rumbo, H., Sanguanprasit, B. & Wichaikull, S., 2016. Factors Influencing Preventive Behaviors of Mothers for Diarrhea in Children Aged 1-5 Years in Buol District, Indonesia. *Sociology Study,* 6(12), pp. 745-753.

Sáez-Llorens, X. & McCracken Jr, G. H., 2003. Bacterial meningitis in children. *The Lancet,* 361(9375), pp. 2139-2148.

Safari, D. dkk., 2014. Serotype Distribution and Antibiotic Susceptibility of Streptococcus pneumoniae Strains Carried by Children Infected with Human Immunodeficiency Virus. *PLoS one,* 9(10), p. 110526.

Sanchez, L., 2008. *Pharmacoeconomic: Principkes, Methods and Aplication in Pharmacotherapy A Pathophysiologic Approach.* 6th ed. New York: McGraw-Hill Companies Inc.

Sandra, D. W., Arsin, A. A. & Mallongi, A., 2015. The Dynamic Model Approach in Estimating Rabies in North Toraja Regency. *International Journal of Sciences: Basic and Applied Research (IJSAR),* 24(1), pp. 421-429.

Sari, L. P. A. & Harahap, M. S., 2013. Perbedaan Mortalitas Antara Pasien Sepsis Dan Sepsis Komplikasi Disseminated Intravascular Coagulation (Dic) Di Icu Rsup Dr. Kariadi. *Jurnal Kedokteran Diponegoro,* 2(1), p. 138565.

Sectish, T. & Charles, G., 2007. *Pneumonia. In: Behrman RE, editor.* Nelson's textbook of pediatrics. 18th ed. New York: WB Saunders.

Setiawan, D., Endarti, D. & Suwantika, A. A., 2017. *Farmakoekonomi Modeling.* Purwokerto: UMP Press.

Sevilla, C., 2007. *Research Methods.* Quezon: Rex Printing Company.

Shoham, Y. dkk., 2005. Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life. *Pediatrics,* 115(5), pp. 1213-1219.

Simatupang, T., 1995. *Pemodelan Sistem.* 1st ed. Klaten: Nindita.

Sinha, A. dkk., 2007. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. *The Lancet,* 369(9559), pp. 389-396.

Sirisuksan, V., Trung, Q. V. & Riewpaiboon, A., 2017. Cost of pneumonia in children: A systematic review. *Mahidol Univ J Pharm,* 44(1), pp. 40-49.

Soewignjo, S. dkk., 2001. Streptococcus pneumoniae Nasopharyngeal Carriage Prevalence, Serotype Distribution, and Resistance Patterns among Children on Lombok Island, Indonesia. *Clinical Infectious Diseases*, 32(7), pp. 1039-1043.

Sohn, H. S., Suh, D.-C., Jang, E. & Kwon, J.-W., 2010. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea. *Journal of Managed Care Pharmacy*, 16(1), pp. 32-45.

Song, J.-H. dkk., 2004[a]. High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). *Antimicrobial Agents and Chemotherapy*, 48(6), pp. 2101-2107.

Song, J.-H. dkk., 2004[b]. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). *Journal of Antimicrobial Chemotherapy*, 53(3), pp. 457-463.

Swanson, D., 2015. Meningitis. *Pediatr Rev*, 36(12), pp. 514-524.

Tam, P.-Y. I., Bernstein, E., Ma, X. & Ferrieri, P., 2015. Blood Culture in Evaluation of Pediatric Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. *Hospital Pediatrics*, 5(6), pp. 324-336.

Tunkel, A. R. dkk., 2004. Practice guidelines for the management of bacterial meningitis. *Clinical Infectious Diseases*, 39(9), pp. 1267-1284.

Tyo, K. R. dkk., 2011. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. *Vaccine*, 29(38), pp. 6686-6694.

United Nations, 2015. *invima.gov.co*. [*Online*] *Available* at: https://www.invima.gov.co/images/pdf/salasespecializadas/Sala_Especializada_de_Medicamentos/acta2011/ACTA_No_12_DE_2011.pdf. [Diunduh Mei 2012].

United Nations Children's Fund (UNICEF), 2021. *Indonesia Menerima 1,6 Juta Dosis Vaksin Pneumokokus Pertama Melalui Mekanisme Advance Market Commitment (AMC) Gavi Untuk Melindungi Anak-anak Dari Pneumonia.* [*Online*] *Available* at: https://www.unicef.org/indonesia/id/press-releases/indonesia-menerima-16-juta-dosis-vaksin-pneumokokus-pertama-melalui-mekanisme. [Diunduh 21 Juli 2021].

Van de Beek, D., Gans, J. d., Tunkel, A. R. & Wijdicks, E. F. M., 2006. Community-Acquired Bacterial Meningitis in Adults. *New England Journal of Medicine*, 354(1), pp. 44-53.

Vidal, A. & Santos, L., 2017. Comorbidities impact on the prognosis of severe acute community-acquired pneumonia. *Porto Biomedical Journal*, 2(6), pp. 265-272.

Vogenberg, F. R., 2001. *Introduction to applied pharmacoeconomics.* New York: The McGraw-Hill Companies, Inc.

Walley, T., 2004. *Pharmacoeconomics*, Philadelphia: Churchill Livingstone Press.

Wardlaw, T. M., Johansson, E. W. & Hodge, M. J., 2006. *Pneumonia the forgotten killer of children.* s.l.:Unicef.

Webster, J. dkk., 2011. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. *BMC Public Health*, 11(3), pp. 1-14.

World Health Organization (WHO), 2007. Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. *Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire*, 82(12), pp. 93-104.

World Health Organization (WHO), 2014. *Principles and Considerations for Adding a Vaccine to a National Immunization Programme: From Decision to Implementation and Monitoring.* [*Online*] *Available at*: http://www.who.int/immunization/documents. [Accessed 21 Juli 2021].

World Health Organization (WHO), 2015[a]. *World Health Organization.* [*Online*] *Available at*: http://www.who.int/gho/countries/idn.pdf?ua=1. [Diunduh 1 Desember 2015].

World Health Organization (WHO), 2015[b]. *World Health Organization.* [*Online*] *Available at*: http://www/who.int/mediacentre/factsheets/fs331/en/. [Diunduh 3 Desember 2015].

Wilson, J. P. & Rascati, K. L., 2001. Pharmacoeconomics. In: P. Malone, M. Mosdell K, L. Kier K & J. E. Stanovich, eds. *Drug Information*: *A Guide for Pharmacist, 2nd edition*. New York: Publishing Div. United State, pp. 209-229.